Ambeed.cn

首页 / / / / Aurantio-obtusin/橙黄决明素

Aurantio-obtusin/橙黄决明素 {[allProObj[0].p_purity_real_show]}

货号:A221042

Aurantio-obtusin是一种天然蒽醌类化合物,具有降血压、降脂、抗炎等作用,能够通过 AMPK/自噬和 AMPK/TFEB 通路改善肝脂肪变性。

Aurantio-obtusin/橙黄决明素 化学结构 CAS号:67979-25-3
Aurantio-obtusin/橙黄决明素 化学结构
CAS号:67979-25-3
Aurantio-obtusin/橙黄决明素 3D分子结构
CAS号:67979-25-3
Aurantio-obtusin/橙黄决明素 化学结构 CAS号:67979-25-3
Aurantio-obtusin/橙黄决明素 3D分子结构 CAS号:67979-25-3
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Aurantio-obtusin/橙黄决明素 纯度/质量文件 产品仅供科研

货号:A221042 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
Cell, 2025. Ambeed. [ A122167 ]
Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >
产品名称 COX COX-1 COX-2 其他靶点 纯度
Piroxicam 98%
Salicylic acid 98%
Phenacetin 98%
Etodolac 99%
Flunixin meglumine 98%
Ibuprofen L-lysine 98%
Nabumetone 98%
Acemetacin 98%
Diflunisal 98%
Pranoprofen 98%
Ampiroxicam 98%
Meloxicam 98%
Sulindac 98%
Ketoprofen 98%
Mefenamic Acid 95%
Bromfenac sodium 98%
Oxaprozin 99%
Aspirin 99%
Nepafenac 98%
Zaltoprofen 99%
Salicin 98%
Suprofen 99%+
Xanthohumol 99%
Parecoxib 98%
Tolfenamic Acid +++

COX-2, IC50: 0.2 μM

98%
Etoricoxib 99%
Niflumic Acid 98%
Valdecoxib ++++

COX-2, IC50: 5 nM

99+%
Ibuprofen +

COX-1, IC50: 13 μM

+

COX-2, IC50: 370 μM

98%
Indomethacin ++

COX1, IC50: 0.28 μM

+

COX-2, IC50: 14 μM

97%
Lornoxicam ++++

COX-1, IC50: 5 nM

++++

COX-2, IC50: 8 nM

98%
Meclofenamic acid sodium ++++

COX-1, IC50: 40 nM

+++

COX-2, IC50: 50 nM

99%
Asaraldehyde 98%
Naproxen +

COX-1, IC50: 8.7 μM

+

COX-2, IC50: 5.2 μM

98%
Diclofenac Sodium Salt +++

COX-1, IC50: 60 nM

+++

COX-2, IC50: 200 nM

98%
NS-398 ++

COX-2, IC50: 3.8 μM

95%
Amfenac Sodium Hydrate ++

COX-1, IC50: 250 nM

+++

COX-2, IC50: 150 nM

98%+
Nimesulide +

COX-2, IC50: 26 μM

98%
Lumiracoxib ++

COX-1, Ki: 3 μM

+++

COX-2, Ki: 60 nM

98%
Rutaecarpine 95%
Celecoxib ++++

COX-2, IC50: 40 nM

98%
Carprofen ++++

canine COX2, IC50: 30 nM

98%
Ketorolac ++

COX-1 (human), IC50: 1.23 μM

++

COX-2 (human), IC50: 3.50 μM

98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Aurantio-obtusin/橙黄决明素 生物活性

描述 GlucoAurantio-obtusin, a natural product isolated and purified from the seeds of Cassia obtusifolia L., possesses hypotensive and hypolipidemic effects.

Aurantio-obtusin/橙黄决明素 细胞实验

Cell Line
Concentration Treated Time Description References
primary mature BAT adipocytes 15 μM 5 days AO significantly increased the activities of mitochondrial complexes I and IV and decreased ATP levels, suggesting that AO promotes energy expenditure by activating UCP1-mediated mitochondrial respiration uncoupling. Acta Pharmacol Sin. 2023 Sep;44(9):1826-1840
Primary BAT adipocytes 15 μM 24 h To study the effect of AO on oxidative stress and mitochondrial function in primary BAT adipocytes, AO reduced oxidative stress and inhibited mPTP opening. Chin Med. 2025 Mar 25;20(1):41
AML12 cells 15 μM 24 h To investigate the effect of AO on inflammation in AML12 cells, AO reduced inflammation in AML12 cells by inhibiting mtDNA release from BAT cells. Chin Med. 2025 Mar 25;20(1):41
HepG2 cells 10-600 µM 48 h To evaluate the inhibitory effect of AO on liver cancer cell activity, the results showed that AO significantly inhibited the proliferation of SK-Hep1 and HepG2 cells. Int J Oncol. 2024 Oct;65(4):92
HepG2 cells 25 μM 3 and 5 h AO effectively promoted autophagy flux in HepG2 cells, as evidenced by a sustained increase in the number of red fluorescent puncta (autolysosomes). Front Pharmacol. 2022 Jan 11;12:826628
Mouse primary hepatocytes (MPHs) 12.5, 25, 50 μM 24 h AO significantly alleviated OAPA-induced lipid accumulation in hepatocytes, dose-dependently reduced the number and size of lipid droplets, and decreased intracellular TG content. Front Pharmacol. 2022 Jan 11;12:826628
RAW264.7 cells 6.25-50 μM 24 h To investigate the anti-inflammatory effects of Aurantio-obtusin on LPS-induced RAW264.7 cells. Results showed that Aurantio-obtusin significantly inhibited the production of NO, PGE2, and reduced the protein expression of COX-2, TNF-α, and IL-6. Molecules. 2018 Nov 27;23(12):3093
Human renal glomerular endothelial cells (HRGECs) 50, 100, 200 µM 48 h To assess the cytotoxic effects of AO on HRGECs. AO caused decreased cell viability, increased LDH leakage, increased secretion of inflammatory cytokines (IL-6, TNF-α, TGF-β1, MCP-1), and decreased ZO-1 expression. Nutrients. 2022 Nov 2;14(21):4615

Aurantio-obtusin/橙黄决明素 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice HFHS diet-induced obese mouse model Oral gavage 10 mg/kg Once daily for 4 weeks AO significantly increased the weight of BAT and accelerated energy expenditure to protect the weight increase in the obese mice. Acta Pharmacol Sin. 2023 Sep;44(9):1826-1840
C57BL/6J mice High-fat diet and glucose-fructose water (HFSW)-induced NAFLD mouse model Oral gavage 5, 10, 15 mg/kg Once daily for 4 weeks AO significantly alleviated HFSW-induced hepatic steatosis, reduced serum ALT and AST levels, decreased hepatic TG and TC content, and improved liver histology. Front Pharmacol. 2022 Jan 11;12:826628
Sprague-Dawley (SD) rats Hepatotoxicity model Oral 4, 40, and 200 mg/kg Once daily for 28 days To study the hepatotoxic effects of Aurantio-obtusin in rats and identify potential biomarkers in urine. Results showed that 23 metabolites were identified as potential biomarkers, with 10 up-regulated and 13 down-regulated. Front Pharmacol. 2020 Aug 12;11:1237
C57BL/6J mice HFHS diet-induced obesity model Oral 10 mg/kg Once daily for 4 weeks To investigate the effect of AO on BAT function and hepatic inflammation in obese mice, AO improved mitochondrial function in BAT and reduced hepatic inflammation. Chin Med. 2025 Mar 25;20(1):41

Aurantio-obtusin/橙黄决明素 参考文献

[1]Yu J, Han JC, Gao YJ. Biotransformation of glucoaurantio-obtusin towards aurantio-obtusin increases the toxicity of irinotecan through increased inhibition towards SN-38 glucuronidation. Phytother Res. 2014 Oct;28(10):1577-80.

[2]Mi BL, Sun Q, et al. Glucuronidation of aurantio-obtusin: identification of human UDP-glucuronosyltransferases and species differences. Xenobiotica. 2014 Aug;44(8):716-21.

Aurantio-obtusin/橙黄决明素 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.03mL

0.61mL

0.30mL

15.14mL

3.03mL

1.51mL

30.28mL

6.06mL

3.03mL

Aurantio-obtusin/橙黄决明素 技术信息

CAS号67979-25-3
分子式C17H14O7
分子量 330.29
SMILES Code O=C1C2=C(C=C(C)C(O)=C2OC)C(C3=CC(O)=C(OC)C(O)=C13)=O
MDL No. MFCD13194886
别名
运输蓝冰
InChI Key RNXZPKOEJUFJON-UHFFFAOYSA-N
Pubchem ID 155011
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry, 2-8°C

溶解方案

DMSO: 25 mg/mL(75.69 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
方案 一
AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。